In the phase II ISPY-2 trial, neoadjuvant durvalumab and olaparib exhibited superior efficacy in terms of pCR over standard NACT in HER2-negative BC, particularly in a highly sensitive subset of high-risk HR-positive, HER2-negative patients (64% vs 22%) (122). The gene discussed is ERBB2; the disease is breast cancer.